New York, NY, and Tel Aviv, ISRAEL – 
(NewMediaWire) – December 6, 2021 – Todos
Medical, Ltd. (OTCQB: TOMDF), a
comprehensive medical diagnostics and related solutions company, today
announced that Todos Medical will be presenting at the upcoming Emerging Growth
Conference to be held on December 8, 2021.
The following are details for
the conference:
Event: Emerging Growth Conference
Date: December 8, 2021
Location: On-Line
Time: Todos Medical Presentation at 3:00pm Eastern
Standard Time
This live, interactive online
event will give existing shareholders and the investment community the
opportunity to interact with the Company’s CEO, Gerald Commissiong, in real
time.
Please register here to ensure
you are able to attend the conference and receive any updates that are
released: https://goto.webcasts.com/starthere.jsp?ei=1512636&tp_key=b542885e5a&sti=tomdf.
If attendees are not able to
join the event live on the day of the conference, an archived webcast will also
be made available on EmergingGrowth.com and we will also release a link to that
after the event.
About the Emerging Growth
Conference
The Emerging Growth conference is
an effective way for public companies to present and communicate their new
products, services and other major announcements to the investment community
from the convenience of their office, in a time efficient manner.
The Conference focus and
coverage includes companies in a wide range of growth sectors, with strong
management teams, innovative products & services, focused strategy,
execution, and the overall potential for long term growth. Its audience
includes potentially tens of thousands of Individual and Institutional
investors, as well as Investment advisors and analysts.
All sessions will be conducted
through video webcasts and will take place in the Eastern Time zone.
For more information, please
visit www.todosmedical.com. For more information
on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
About Todos Medical Ltd.
Founded in Rehovot, Israel with
offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers
life-saving diagnostic solutions for the early detection of a variety of
cancers. In 2021, Todos completed the acquisition of U.S.-based medical
diagnostics company Provista Diagnostics, Inc. to gain rights to its
Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID
testing and Provista’s proprietary commercial-stage Videssa® breast cancer
blood test. The Company’s state-of-the-art and patented Todos Biochemical
Infrared Analyses (TBIA) is a proprietary cancer-screening technology using
peripheral blood analysis that deploys deep examination into cancer’s influence
on the immune system, looking for biochemical changes in blood mononuclear
cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1
and TMB-2, have received a CE mark in Europe. Todos is focused on the
commercialization of Videssa and will bring the TBIA tests to market
thereafter.
Todos has entered into a joint
venture with NLC Pharma targeting diagnostic and testing solutions to address
the COVID-19 pandemic. The Joint-Venture is pursuing the development of
diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors
that target a fundamental reproductive mechanism of coronaviruses. The
Company’s proprietary therapeutic candidate Tollovir™ is currently in a Phase 2
clinical trial to treat hospitalized COVID-19 patients in Israel, and is
preparing to initiate Phase 2/3 clinical trials for both hospitalized and
non-hospitalized patients in Israel.
Todos is also developing blood
tests for the early detection of neurodegenerative disorders, such as
Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a
diagnostic blood test that determines the ability of peripheral blood
lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic
stimulation that induces them to enter the cell cycle. It is believed that
certain diseases, most notably Alzheimer’s disease, are the result of
compromised cellular machinery that leads to aberrant cell cycle re-entry by
neurons, which then leads to apoptosis. LymPro is unique in the use of
peripheral blood lymphocytes as a surrogate for neuronal cell function,
suggesting a common relationship between PBLs and neurons in the brain.
Todos is also distributing
certain (COVID-19) testing materials and supplies to CLIA-certified labs in the
United States. The products cover multiple suppliers of PCR testing kits,
extraction kits, automation materials and supplies, as well as COVID-19
antibody and antigen testing kits.
For more information, please
visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in
this press release may constitute forward-looking statements. For example,
forward-looking statements are used when discussing our expected clinical
development programs and clinical trials. These forward-looking statements are
based only on current expectations of management, and are subject to
significant risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost, and results
of clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for product candidates;
competition from other biotechnology companies; and our ability to obtain
additional funding required to conduct our research, development and
commercialization activities. In addition, the following factors, among others,
could cause actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements;
delays or obstacles in launching our clinical trials; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress further and
lack of acceptance of our methods by the scientific community; inability to
retain or attract key employees whose knowledge is essential to the development
of our products; unforeseen scientific difficulties that may develop with our
process; greater cost of final product than anticipated; loss of market share
and pressure on pricing resulting from competition; and laboratory results that
do not translate to equally good results in real settings, all of which could
cause the actual results or performance to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Todos Medical does not undertake any obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. For a more detailed description of the risks and
uncertainties affecting Todos Medical, please refer to its reports filed from
time to time with the U.S. Securities and Exchange Commission.
Todos
Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com